Skip to main content

Table 1 The main characteristics of included 20 studies

From: Prognostic value of low microRNA-34a expression in human gastrointestinal cancer: a systematic review and meta-analysis

Study

Year

Country

Type

Design

Sample

Num.

Stage

Cut-off

Follow-up

Test method

Outcome

Hu et al. [21]

2011

America

EC

R

Tissue

99

I-IV

Median

> 250

qRT-PCR

OS/DFS

Lin et al. [29]

2015

China

EC

R

Tissue

111

I-IV

Median

NR

qRT-PCR

OS

Osawa et al. [24]

2011

Japan

GC

R

Tissue

37

II-III

70%

60

qRT-PCR

OS

Hui et al. [22]

2015

China

GC

R

Tissue

76

I-III

Mean

> 60

qRT-PCR

OS

Wei et al. [30]

2015

China

GC

R

Tissue

157

I-IV

NR

> 100

qRT-PCR

OS

Zhang et al. [31]

2015

China

GC

R

Tissue

137

I-IV

2.44

68

qRT-PCR

OS

Yang et al. [23]

2015

China

GC

R

Tissue

50

I-IV

Median

60

qRT-PCR

OS

Li et al. [32]

2015

China

HCC

R

Tissue

114

I-IV

ROC

90

qRT-PCR

OS/PFS

Yang et al. [33]

2013

China

HCC

R

Tissue

30

NR

Mean

60

qRT-PCR

OS

Cui et al. [34]

2015

China

HCC

R

Tissue

120

NR

Median

60

qRT-PCR

OS/RFS

Xu et al. [20]

2015

China

HCC

R

Tissue

75

I-IV

Median

60

qRT-PCR

OS/RFS

Ohuchida et al. [35]

2011

Japan

PC

R

Tissue

90

NR

NR

>100

qRT-PCR

OS

Jamieson et al. [36]

2012

Scotland

PC

R

Tissue

72

NR

Median

48

qRT-PCR

OS

Long et al. [10]

2016

China

PC

R

plasma

159

I-IV

Mean

24

qRT-PCR

OS

Sun et al. [37]

2018

China

PC

R

Tissue

139

I-IV

Mean

60

qRT-PCR

OS

Zhang et al. [25]

2017

China

CRC

R

Tissue

84

I-IV

2

36

qRT-PCR

OS

Hasakova et al. [38]

2019

Slovakia

CRC

R

Tissue

64

I-IV

Median

100

qRT-PCR

OS

Gao et al. [39]

2014

China

CRC

R

Tissue

205

II-III

0.307

>80

qRT-PCR

DFS

Gao et al. [39]

2014

China

CRC

R

Tissue

63

II-III

0.307

>80

qRT-PCR

DFS

Jin et al. [11]

2013

China

GBC

R

Tissue

77

NR

Mean

24

qRT-PCR

OS

  1. Abbreviations: CRC colorectal cancer; DFS disease-free survival, EC esophageal cancer; GBC gallbladder cancer; GC gastric cancer; HCC hepatocellular carcinoma, NR no report, OS overall survival, PC pancreatic cancer, PFS progressive-free survival, qRT-PCR quantitative real-time PCR, R retrospective, RFS recurrence-free survival